---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007206"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2026-09-17T12:03:36+00:00"
generated_at: "2026-09-17T12:05:17.158866+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical to merge with North Immunology in $150M all-stock deal; $180M PIPE backs NOR-101

## Summary
- All-stock merger values North Immunology at $150M and Aethlon at $16.5M; closing expected by June 17, 2027.
- North Immunology stockholders to own ~95.25% of combined company; Aethlon holders ~4.75%.
- Oversubscribed $180M private placement ($146M cash + $34M notes) funds operations into 2H 2028.
- NOR-101 (IL-13 x IL-18 bispecific) for atopic dermatitis: Phase 1a Q1 2027, Phase 1b/2b data 2028.
- Legacy Aethlon assets to receive contingent value rights (CVRs) with no guaranteed payments.

## SEC filing metadata
- accession: 0001683168-26-007206
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2026-09-17T12:03:36+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 5.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316826007206/0001683168-26-007206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316826007206/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007206
- JSON: https://secwatch.observer/filing/0001683168-26-007206.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.